Shopping Cart 0
Cart Subtotal
USD 0

NGM Biopharmaceuticals Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Single User License
USD 250

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Site License
USD 500

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Deliverable Format : Excel, PDF Via Email

Corporate User License
USD 750
  • Details
  • Table Of Content
  • Licence Rights
  • Section Purchase
  • Products and Companies

Details

Summary

NGM Biopharmaceuticals Inc (NGM Bio) is a clinical-stage biopharmaceutical company that develops pipeline of biological therapeutics for the treatment of cardio-metabolic, immuno-oncology, retinal and liver diseases. The company's pipeline products include NGM282, NGM386, NGM395, NGM621, NGM313, NGM217 and NGM120. Its NGM313 is an agonistic antibody of the beta-klotho pathway and development candidate for the treatment of metabolic conditions such as type 2 diabetes, obesity and non-alcoholic steatohepatitis. NGM Bio's NGM282 is an engineered protein variant of FGF19 for the treatment of non-alcoholic steatohepatitis and bile acid-related diseases. The company's biologics platform incorporates multiple technologies to generate and screen monoclonal antibodies. NGM Bio is headquartered in San Francisco, California, the US.

NGM Biopharmaceuticals Inc-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 3

List of Tables 4

List of Figures 4

NGM Biopharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

NGM Biopharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6

NGM Biopharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

NGM Biopharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

NGM Biopharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9

NGM Biopharmaceuticals Inc, Pharmaceuticals & Healthcare, Deal Details 10

Venture Financing 10

NGM Biopharma Raises USD106 Million in Series E Financing 10

NGM Biopharmaceuticals Secures USD 36.8 Million Series D Financing 11

NGM Biopharma Raises USD20.7 Million in Series D Financing 12

NGM Biopharma Raises USD 50 Million In Series C Venture Financing 13

Partnerships 14

NGM Biopharma Enters into R&D Agreement with Merck for Novel Biologic Therapeutics 14

MedImmune Enters Into Co-Development Agreement With NGM Biopharma 15

Daiichi Sankyo Enters Into Co-Development Agreement With NGM Biopharma For Diabetes Drugs 16

Licensing Agreements 17

Ablexis Enters into Licensing Agreement with NGM Biopharma 17

NGM Biopharma Enters Into Licensing Agreement With Janssen Pharma For New Diabetes Drugs 18

Equity Offering 19

NGM Biopharma Files Registration Statement to Raise up to USD75 Million IPO of Shares 19

NGM Biopharmaceuticals Inc-Key Competitors 20

NGM Biopharmaceuticals Inc-Key Employees 21

NGM Biopharmaceuticals Inc-Locations And Subsidiaries 22

Head Office 22

Recent Developments 23

Corporate Communications 23

Oct 01, 2018: NGM Biopharmaceuticals names David J. Woodhouse as Chief Executive Officer and Aetna Wun Trombley as President and Chief Operating Officer 23

Appendix 25

Methodology 25

About GlobalData 25

Contact Us 25

Disclaimer 25


List Of Figure

List of Figures

NGM Biopharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

NGM Biopharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

NGM Biopharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

NGM Biopharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

NGM Biopharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

NGM Biopharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6

NGM Biopharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

NGM Biopharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8


List Of Table

List of Tables

NGM Biopharmaceuticals Inc, Pharmaceuticals & Healthcare, Key Facts 2

NGM Biopharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

NGM Biopharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6

NGM Biopharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

NGM Biopharmaceuticals Inc, Deals By Therapy Area, 2012 to YTD 2018 8

NGM Biopharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9

NGM Biopharma Raises USD106 Million in Series E Financing 10

NGM Biopharmaceuticals Secures USD 36.8 Million Series D Financing 11

NGM Biopharma Raises USD20.7 Million in Series D Financing 12

NGM Biopharma Raises USD 50 Million In Series C Venture Financing 13

NGM Biopharma Enters into R&D Agreement with Merck for Novel Biologic Therapeutics 14

MedImmune Enters Into Co-Development Agreement With NGM Biopharma 15

Daiichi Sankyo Enters Into Co-Development Agreement With NGM Biopharma For Diabetes Drugs 16

Ablexis Enters into Licensing Agreement with NGM Biopharma 17

NGM Biopharma Enters Into Licensing Agreement With Janssen Pharma For New Diabetes Drugs 18

NGM Biopharma Files Registration Statement to Raise up to USD75 Million IPO of Shares 19

NGM Biopharmaceuticals Inc, Key Competitors 20

NGM Biopharmaceuticals Inc, Key Employees 21

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Products and Companies

Products

NGM Biopharmaceuticals Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.